---
title: "Celcuity 在 2025 年 ESMO 大会上展示了 1 期研究的更新数据，该研究评估了 Gedatolisib 联合 Darolutamide 在患有转移性去势抵抗性前列腺癌（“mCRPC”）男性中的效果"
description: "中位放射学进展自由生存期（\"rPFS\"）为 9.1 个月，六个月 rPFS 率为 67%。没有患者因治疗相关不良事件（\"TRAE\"）而中断研究治疗"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/261722768.md"
published_at: "2025-10-18T09:07:39.000Z"
---

# Celcuity 在 2025 年 ESMO 大会上展示了 1 期研究的更新数据，该研究评估了 Gedatolisib 联合 Darolutamide 在患有转移性去势抵抗性前列腺癌（“mCRPC”）男性中的效果

> 中位放射学进展自由生存期（"rPFS"）为 9.1 个月，六个月 rPFS 率为 67%。没有患者因治疗相关不良事件（"TRAE"）而中断研究治疗

Median radiographic progression free survival ( "rPFS" ) was 9.1 months and the six-month rPFS rate was 67% No patients discontinued study treatment due to a treatment-related adverse event ( "TRAE" )

### Related Stocks

- [CELC.US - Celcuity](https://longbridge.com/zh-CN/quote/CELC.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Celcuity CEO Sets July 17 PDUFA for Gedatolisib, Teases VIKTORIA-1 Mutant Data at Conference | Celcuity CEO Brian Sullivan announced a PDUFA date of July 17 for gedatolisib's NDA during the Guggenheim Healthcare Con | [Link](https://longbridge.com/zh-CN/news/275700086.md) |
| Celcuity Q3 Adjusted Loss Widens | Celcuity Q3 Adjusted Loss Widens | [Link](https://longbridge.com/zh-CN/news/265587075.md) |
| The Numbers are Clear: Latest Iteration of Stagwell's News Advertising Study Shows Germans Love Their News  \| STGW Stock News | Stagwell, in partnership with Axel Springer, Teads, and The Trade Desk, released a study revealing that 81% of German ad | [Link](https://longbridge.com/zh-CN/news/276214836.md) |
| ISG to Study Providers of AI-ready Infrastructure Solutions \| III Stock News | ISG has launched a research study to evaluate providers of AI-ready infrastructure solutions, focusing on their ability  | [Link](https://longbridge.com/zh-CN/news/276145387.md) |
| Oncoinvent to Present Positive 24-month Follow-up Data from Phase 1 Ovarian Cancer Study of Radspherin[®] at ESGO 2026 | Oncoinvent will present positive 24-month follow-up data from its Phase 1 study of Radspherin[®] for ovarian cancer at E | [Link](https://longbridge.com/zh-CN/news/276096935.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。